Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03593993 · ClinicalTrials.gov registry record
A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas
A clinical trial, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- 3
- Enrollment target
NCT03593993: Clinical Trial study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT03593993 is a clinical trial that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03593993 was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- 3 participants
- Enrollment target
Study Summary
This is a surgical biospecimen collection study. The purpose of this study is to understand how much of two drugs (dabrafenib and trametinib) are able to penetrate brain tumors and turn off the RAF signaling pathway. This is important because these drugs are currently FDA approved for other tumors and may have efficacy in brain tumors with the BRAF V600E mutation.
Primary Outcome
Obtain single time-point concentration of dabrafenib in enhancing brain tissue (ng/mL) using liquid chromatography/mass spectrometry with one single, random sample
Interventions
- PROCEDURE Surgical Cohort
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-05-19 |
| Est. Completion | 2023-07-07 |
Why NCT03593993 stopped before completion
NCT03593993 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 3 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Surgical Cohort is the first listed.
NCT03593993 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03593993 about?
NCT03593993 is a clinical study titled "A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas". This is a surgical biospecimen collection study. The purpose of this study is to understand how much of two drugs (dabrafenib and trametinib) are able to penetrate brain tumors and turn off the RAF signaling pathway. This is important because these drugs are currently FDA approved for other tumors a...
What is the current status of trial NCT03593993?
This trial is currently terminated. The enrollment target is 3 participants. The study started on 2018-05-19. Estimated completion is 2023-07-07.
What interventions are being tested in trial NCT03593993?
The interventions under investigation include: Surgical Cohort (PROCEDURE).
Who is sponsoring clinical trial NCT03593993?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI